Codagenix is a clinical stage synthetic biology company that uses a machine learning-informed engineering platform to re-design viral genomes, constructing codon-modified viruses to prevent viral infections or treat cancer. Codagenix is developing a robust pipeline of clinical and pre-clinical stage vaccines. At LabCentral 238, we are expanding the use of codon modified viruses as immunotherapeutics for solid tumors, robustly activating multiple steps in the cancer immunity cycle. Viruses for both disease areas are compatible with existing scalable and low-cost manufacturing systems.
- J. Robert Coleman CEO and Co-Founder
- Steffen Mueller CSO and Co-Founder
- Tyler Cook CFO
- Johanna Kaufmann EVP Oncology
- Sybil Tasker CMO